More Blood Monocytes May Mean Greater Risk for Lung Abnormalities

Pulmonary Fibrosis Foundation Welcomes ‘Ambassador’ Applicants

The Pulmonary Fibrosis Foundation (PFF) is welcoming pulmonary fibrosis (PF) patients, caregivers, and lung transplant recipients in the U.S. willing to volunteer as PFF Ambassadors. The PFF Ambassador program is designed to offer hope and inspiration to those affected by PF through public speaking and heightened awareness of this…

Algernon Secures Canadian Patent of NP-120 for IPF

Algernon Pharmaceuticals has been notified it will be given a Canadian patent, as requested, covering its investigational oral therapy NP-120 (ifenprodil) for idiopathic pulmonary fibrosis (IPF). Initially developed by Sanofi and approved for the treatment of circulatory disorders in Japan and South Korea, ifenprodil showed anti-scarring and anti-coughing effects…

High-Flow Oxygen Therapy Can Boost Exercise for Select IPF Patients

Supplementary oxygen using a high‐flow nasal cannula boosts exercise endurance more effectively than standard devices in idiopathic pulmonary fibrosis (IPF) patients with suboptimal blood-oxygen levels, a small trial reported. The study, “Impact of high-flow oxygen therapy during exercise in idiopathic pulmonary fibrosis: a pilot crossover clinical trial,” was…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums